Yahoo

4 Cardiogenic Shock Symptoms Doctors Urge Women Over 50 To Never Ignore

Add Yahoo as a preferred source to see more of our stories on Google. Most people who've had a heart attack—or who fear having one—focus on surviving the cardiovascular event itself. But what happens ...
TCTMD

The Contemporary Management of Cardiogenic Shock in the Post DanGer-Shock Era?

PE Interventions in 2030: What Do Future Devices Offer? Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular ...

Etiometry Receives a First-Ever FDA Clearance for Automating Hospital-Specific Cardiogenic Shock Classification and Tracking

Etiometry, a leader in AI-driven clinical intelligence, today announced it has received FDA clearance (K254066) for the first-ever solution for automation of hospital-specific cardiogenic shock ...

Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., /PRNewswire/ -- Supira Medical, Inc. (Supira), a c ...
Medscape

Early-Onset AKI Tied to Poor Prognosis in Cardiogenic Shock

In infarct-related cardiogenic shock, acute kidney injury (AKI) occurring within 48 hours was identified as a high-risk haemodynamic phenotype — marked by severe haemodynamic instability, metabolic ...
TCTMD

AI-Enabled Real-Time Shock Navigator for Precision Decision-Making in Cardiogenic Shock

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Microaxial flow pump does not improve outcomes for high-risk heart attack patients without cardiogenic shock: Trial

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage. That is ...

Supira Medical, Inc.: Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

SUPPORT II (SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)) is a prospective, randomized controlled study designed to assess the safety and efficacy of the c ...